Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 9 (5) |
| Completed vs Stopped Early | 4 / 4 (23.5%) |
| Median Closed Actual Enrollment | 147 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Kantonsspital St. Gallen | Sankt Gallen | 6 |
| Inselspital Bern | Bern | 5 |
| CHU Angers | Angers | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC | Phase II | RECRUITING |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Ce | Phase III | RECRUITING |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non- | Phase III | RECRUITING |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Ca | Phase III | RECRUITING |
| NCT04908956 | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the ETOP IBCSG Partners Foundation Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.